不同剂量美常安对溃疡性结肠炎患者维持治疗的临床对比研究  

Therapeutic effect of different dose Medilac-S on the maintenance of remission in ulcerative colitis

作　　者：王玮[1] 张露[2] 占义军[1] 莫慧琴[1] 

机构地区：[1]湖北省襄阳市中心医院&湖北文理学院附属医院消化内科,湖北襄阳441021 [2]湖北省襄阳市中心医院&湖北文理学院附属医院重症医学科,湖北襄阳441021

出　　处：《胃肠病学和肝病学杂志》2016年第1期59-61,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的比较小剂量和标准剂量美常安对溃疡性结肠炎(ulcerative colitis,UC)患者维持治疗的疗效及安全性。方法选取2012年6月-2013年12月于湖北省襄阳市中心医院就诊的UC缓解期患者98例,随机分为3组:美沙拉嗪组,口服美沙拉嗪缓释颗粒1.5 g/d;小剂量美常安组,口服美常安750 mg/d;标准剂量美常安组,口服美常安1 500 mg/d。所有患者随访6个月,观察并记录维持缓解时间、不良反应情况,所有患者复查肠镜并记录UC活动度积分和病理组织学积分。结果三组患者UC复发率、维持缓解时间、肠镜活动度积分及病理组织学积分差异均无统计学意义(P>0.05)。结论小剂量美常安在UC患者维持治疗中是安全、有效的。Objective To compare the therapeutic effect and safety of standard-dose and low-dose Medilac-S on the maintenance of remission in ulcerative colitis （ UC）. Methods Ninety-eight patients diagnosed as UC in remission were recruited and divided into 3 groups ： Mesalazine group received Mesalazine 1.5 g/d ; low-dose Medilac-S group received Medilac-S 750 mg/d; standard-dose Medilac-S group received Medilac-S1 500 mg/d. The study lasted for 6 months and patients were assessed by clinical and endoscopic activity indices by histology as well. Results There was no difference in relapse rate, relapse-free time, endoscopic activity indices and histology indices among 3 groups （P 〉 0.05）. Conclusion Low-dose Medilac-S is effective and safe in maintaining remission in patients with UC.

关 键 词：溃疡性结肠炎 肠道菌群 益生菌 美常安 

分 类 号：R574.62[医药卫生—消化系统]